PET/SPECT圖像以及治療領域的全球核醫學（醫療用同位素／放射性同位素／放射性醫藥品）市場：競爭環境、現況、預測（2010∼2015年）

PET/SPECT圖像以及治療領域的全球核醫學（醫療用同位素／放射性同位素／放射性醫藥品）市場：競爭環境、現況、預測（2010∼2015年） 是由出版商Markets and Markets在2011年08月所出版的。 這份英文市場調查報告書包含255 Pages 價格從美金4650起跳。

簡介

放射性藥品是診斷出心臟病與癌症、神經疾病等症狀時，用於癌症等治療的藥品。做為追蹤用的放射性藥品之使用可以追溯到1930年代。之後，生產、診斷裝置等技術進歩與新的放射性藥品的創藥等擴大了該市場。全球PET/SPECT圖像用的放射性藥品市場在2010年為32億1,300萬美元，2015年預測可達到47億3,400萬美元。

本報告書為PET/SPECT圖像用放射性藥品市場之相關調査分析、投藥路徑、應用、各地區動向、收益預測、各子市場的動向等整理，概述如下。

總綱

第1章 導論

• 整理
• 報告書詳細
• 市場的範圍
• 利益關係人
• 調査手法

第2章 摘要

第3章 市場概要

• 放射性藥品定義
• 發展
• 市場劃分
• 促進力分析
  • 促進因子
  • 阻礙因子
  • 威脅
  • 機會
• 必要事項
• 課題
• 市場佔有率分析
• 末端使用者分析
• 競爭分析
• 專利分析
• 將來的放射性藥品

第4章 放射性同位素市場：依同位素

• 導論
• FLUDEOXYGLUCOSE
• 锝
• 鉈
• 鎵
• 碘化鈉
• IOBENGUANE
• 錸
• 釤
• 釔
• 鉺
• 其他

第5章 各投藥路徑放射性藥品

• 導論
• 血管内投藥
• 吸入投藥
• 個別投藥
• 其他

第6章 各用途放射性藥品

• 導論
• 診斷用放射性藥品
  • 單光子放出電腦斷層攝影（SPECT）
  • 陽電子放出斷層攝影（PET）
• 各診斷適應放射性藥品市場
• 治療／放射性核種治療用放射性藥品

第7章 放射性藥品生產相關的法規體制上課題

• 導論
• 安全性
• 設備・裝置
• 輸送導覽
• 歐洲的導覽
• 美國的導覽
• 償還

第8章 各地區市場（消費）

• 導論
• 北美
• 歐洲
• 日本
• 全球其他地區

第9章 各地區市場（生產）

• 導論
• 北美
• 歐洲
• 亞太地區
• 日本
• 全球其他地區

第10章 競爭情勢

• 主要戰略

第11章 企業簡介

附錄

圖表

目錄

Abstract

Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930's. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.

Diagnostic applications of radiopharmaceuticals have around 90% of the market share. The market is growing due to the increasing incidences of cancer and cardiac diseases, requisition of better imaging techniques for diseases such as Alzheimer's. Targeted alpha therapy is one of the most promising treatments for cancer, which is being researched upon by cancer institutes.

Driven by the increasing incidence of cardiac and cancer diseases, early and accurate diagnosis, increasing awareness amongst the masses, and expanding application segment; the global radiopharmaceutical market reached around $3.2 billion in 2010. Radiopharmaceuticals are used for the diagnosis and treatment of various ailments such as cancer, cardiac, renal, and respiratory diseases among the others. PET machines enable radiologists in early detection of cancer, cardiac, and Alzheimer's disease among the patients. This would increase the demand for PET machines among the healthcare centers and providers. Similarly, SPECT scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape with opportunities in the market for neuroendocrine tumor imaging. For diagnostic applications of radiopharmaceuticals, radioisotopes such as FDG for PET and technetium for SPECT are most commonly used.

PET and SPECT scans provide dynamic images of the body's interior, rather than just the bones, like X-ray and magnetic resonance imaging (MRI). PET scan lets the doctor identify glucose metabolism in different parts of the body in a patient. Cancer cells grow at a faster rate than the other cells. The machine detects the speed of glucose being used and indicates the presence of cancerous tumors. The cancerous cell breaks down glucose at a higher rate than the other cells and this increased activity can be seen in a scan. Thus, the use of PET and SPECT scans facilitates early and accurate diagnosis of diseases such as cancer. Increased usage of PET & SPECT scans in turn increases the demand for radiopharmaceuticals.

FDG is the major radiopharmaceutical used in PET (approximately 90%). PET procedures are preferred over SPECT as PET is more accurate, sensitive, and endowed with better spatial arrangement of the image. Besides, the main radiopharmaceutical used in SPECT; i.e. technetium (99m) has a limited supply, forcing people to look for alternatives. FDG can be produced at desired levels to meet all the imaging requirements. This situation is boosting the FDG market.

Most of the radiopharmaceuticals are used in hospitals; accounting for 92%. Majority of the radiopharmaceuticals are administered intravenously. The market for radiopharmaceuticals is restricted by their high cost and difficulties faced while transporting them.

This research report categorizes the radiopharmaceuticals therapy and PET/SPECT imaging market on the basis of isotopes, routes of administration, applications, and geography; forecasting revenue, and analyzing trends in each of the following submarkets:

On the basis of isotopes:

Fludeoxyglucose (F18), Technetium (Tc99m), Gallium (Ga67), Sodium Iodide (I123), Iobenguane (I131), Rhenium (Re186), Samarium (Sm153),Thallium (Tl201), Yttrium (Y90), Erbium(Er169), and others

On the basis of routes of administration:

Intravenous, peroral, inhalation, and others

On the basis of applications:

Diagnosis (PET and SPECT), indication for diagnosis, and therapy

On the basis of geography:

North America (U.S. and Canada), Europe, Asia-Pacific, Japan, and Rest of the World

Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments. In addition, the report provides more than 16 company profiles covering all the sub-segments.

FACTORS DRIVING THE RADIOPHARMACEUTICALS MARKET

Source: MarketsandMarkets analysis

EXECUTIVE SUMMARY

• MARKET SCENARIO

1. INTRODUCTION

• 1.1. KEY TAKE-AWAYS
• 1.2. REPORT DESCRIPTION
• 1.3. MARKETS COVERED
• 1.4. STAKEHOLDERS
• 1.5. RESEARCH METHODOLOGY

2. SUMMARY

3. MARKET OVERVIEW

• 3.1. DEFINITION OF RADIOPHARMACEUTICALS
• 3.2. EVOLUTION
• 3.3. MARKET SEGMENTATION
• 3.4. DRIVING FORCE ANALYSIS
  • 3.4.1. DRIVERS
    • 3.4.1.1. Increasing incidence of cancer and cardiac ailments
    • 3.4.1.2. Increasing use of SPECT and PET scans
    • 3.4.1.3. Rising awareness of Radiopharmaceuticals among physicians
    • 3.4.1.4. Alpha radioimmunotherapy-based targeted cancer treatment
    • 3.4.1.5. Ready availability of radiopharmaceuticals from cyclotrons
  • 3.4.2. RESTRAINTS
    • 3.4.2.1. Half-life of radiopharmaceuticals
    • 3.4.2.2. High capital demand
    • 3.4.2.3. Lack of good manufacturing practices (GMP)
    • 3.4.2.4. Inefficient effluent treatment management
    • 3.4.2.5. Stringent regulatory guidelines
  • 3.4.3. THREAT
    • 3.4.3.1. Shutdown of nuclear reactors impacts the production of radioisotopes
  • 3.4.4. OPPORTUNITIES
    • 3.4.4.1. Increasing demand for diagnosis
    • 3.4.4.2. High demand in geographies with inadequate supply
• 3.5. WINNING IMPERATIVES
  • 3.5.1. INTRODUCTION OF NEW AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  • 3.5.2. INCREASING REGULATORY APPROVALS OF RADIOPHARMACEUTICALS
• 3.6. BURNING ISSUES
  • 3.6.1. HIGH COST OF IMAGING DEVICES
  • 3.6.2. SHORTAGE IN SUPPLY OF TECHNETIUM-99M (RADIOISOTOPE)
• 3.7. MARKET SHARE ANALYSIS
• 3.8. END-USER ANALYSIS
• 3.9. COMPETITIVE ANALYSIS
• 3.10. PATENT ANALYSIS
• 3.11. FUTURE RADIOPHARMACEUTICALS

4. RADIOPHARMACEUTICAL MARKET, BY ISOTOPES

• 4.1. INTRODUCTION
• 4.2. FLUDEOXYGLUCOSE (18F)
  • 4.2.1. INCREASE IN AVAILABILITY OF HYBRID PET/CT MACHINES
  • 4.2.2. RISE IN PET PROCEDURES INCREASES DEMAND FOR FDG
  • 4.2.3. HIGH GENERATION COSTS OF FDG
  • 4.2.4. NEED FOR SPEEDY & EFFICIENT TRANSPORTATION
• 4.3. TECHNETIUM (99MTC)
  • 4.3.1. TECHNETIUM CAN COMBINE WITH 31 DIFFERENT CARRIER MOLECULES
  • 4.3.2. LACK OF AVAILABILITY OF TECHNETIUM
• 4.4. THALLIUM (201TL)
  • 4.4.1. THALLIUM MOST COMMON SUBSTITUTE OF TECHNETIUM
• 4.5. GALLIUM (67GA)
• 4.6. SODIUM IODIDE (123I)
• 4.7. IOBENGUANE (131I)
• 4.8. RHENIUM (186RE)
• 4.9. SAMARIUM (153SM)
• 4.10. YTTRIUM (90Y)
• 4.11. ERBIUM (169ER)
• 4.12. OTHERS

5. RADIOPHARMACEUTICAL MARKET, BY ROUTES OF ADMINISTRATION (ROA)

• 5.1. INTRODUCTION
• 5.2. INTRAVENOUS ADMINISTRATION
• 5.3. INHALATION ADMINISTRATION
• 5.4. PERORAL ADMINISTRATION
• 5.5. OTHER ROUTES OF ADMINISTRATION

6. RADIOPHARMACEUTICAL MARKET, BY APPLICATIONS

• 6.1. INTRODUCTION
• 6.2. RADIOPHARMACEUTICALS FOR DIAGNOSIS
  • 6.2.1. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IMAGING
    • 6.2.1.1. Introduction
    • 6.2.1.2. Principle & procedure
    • 6.2.1.3. Radiotracers
    • 6.2.1.4. Limitations
    • 6.2.1.5. Safety
    • 6.2.1.6. Radiopharmaceuticals
      • 6.2.1.6.1. Technetium-99m
      • 6.2.1.6.2. Gallium (67Ga)
      • 6.2.1.6.3. Sodium iodide (123I)
      • 6.2.1.6.4. Iobenguane (131I)
      • 6.2.1.6.5. Rhenium (186Re)
      • 6.2.1.6.6. Thallium (201Tl)
      • 6.2.1.6.7. Yttrium (90Y)
      • 6.2.1.6.8. Others
  • 6.2.2. POSITRON EMISSION TOMOGRAPHY (PET) IMAGING
    • 6.2.2.1. Introduction
    • 6.2.2.2. Principle & procedure
    • 6.2.2.3. Radiotracers
    • 6.2.2.4. Limitations
    • 6.2.2.5. Safety
    • 6.2.2.6. Radiopharmaceuticals
      • 6.2.2.6.1. 18F-FD/Fluorodeoxyglucose (18F)
      • 6.2.2.6.2. Others
• 6.3. RADIOPHARMACEUTICAL MARKET, BY INDICATION FOR DIAGNOSIS
  • 6.3.1. INTRODUCTION
  • 6.3.2. CARDIAC DISEASES
  • 6.3.3. NEUROIMAGING
  • 6.3.4. BONE SCAN
  • 6.3.5. LIVER SCAN
  • 6.3.6. RESPIRATORY SCAN
  • 6.3.7. RENAL SCAN
  • 6.3.8. THYROID SCAN
• 6.4. RADIOPHARMACEUTICALS FOR TREATMENT/RADIONUCLIDE THERAPY (RNT)
  • 6.4.1. TARGETED ALPHA THERAPY (TAT) OR ALPHA RADIOIMMUNOTHERAPY
  • 6.4.2. RADIOPHARMACEUTICALS
    • 6.4.2.1. Iobenguane (131I)
    • 6.4.2.2. Rhenium (186Re)
    • 6.4.2.3. Samarium (153Sm)
    • 6.4.2.4. Erbium (Er169)
    • 6.4.2.5. Others

7. REGULATORY CHALLENGES FOR RADIOPHARMACEUTICALS PRODUCTION

• 7.1. INTRODUCTION
• 7.2. SAFETY OF PERSONNEL
• 7.3. EQUIPMENT & FACILITY
• 7.4. TRANSPORTATION GUIDELINES
• 7.5. GUIDELINES IN EUROPE
• 7.6. GUIDELINES IN U.S.
• 7.7. REIMBURSEMENT

8. GEOGRAPHIC ANALYSIS (CONSUMPTION)

• 8.1. INTRODUCTION
• 8.2. NORTH AMERICA
  • 8.2.1. U.S.
  • 8.2.2. CANADA
• 8.3. EUROPE
• 8.4. APAC (EXCLUDING JAPAN)
• 8.5. JAPAN
• 8.6. REST OF THE WORLD (ROW)

9. GEOGRAPHIC ANALYSIS (PRODUCTION)

• 9.1. INTRODUCTION
• 9.2. NORTH AMERICA
• 9.3. EUROPE
• 9.4. APAC (EXCLUDING JAPAN)
• 9.5. JAPAN
• 9.6. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

11. COMPANY PROFILES

• 11.1. AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
  • 11.1.1. OVERVIEW
  • 11.1.2. PRODUCTS & SERVICES
  • 11.1.3. FINANCIALS
  • 11.1.4. STRATEGY
  • 11.1.5. DEVELOPMENTS
• 11.2. BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
  • 11.2.1. OVERVIEW
  • 11.2.2. PRODUCTS & SERVICES
• 11.3. CARDINAL HEALTH INC.
  • 11.3.1. OVERVIEW
  • 11.3.2. PRODUCTS & SERVICES
  • 11.3.3. FINANCIALS
  • 11.3.4. STRATEGY
  • 11.3.5. DEVELOPMENTS
• 11.4. COVIDIEN PLC
  • 11.4.1. OVERVIEW
  • 11.4.2. PRODUCTS & SERVICES
  • 11.4.3. FINANCIALS
  • 11.4.4. STRATEGY
  • 11.4.5. DEVELOPMENTS
• 11.5. ECZACIBASI-MONROL
  • 11.5.1. OVERVIEW
  • 11.5.2. PRODUCTS & SERVICES
  • 11.5.3. STRATEGY
  • 11.5.4. FINANCIALS
  • 11.5.5. DEVELOPMENTS
• 11.6. FUJIFILM HOLDINGS CORP
  • 11.6.1. OVERVIEW
  • 11.6.2. PRODUCTS & SERVICES
  • 11.6.3. FINANCIALS
  • 11.6.4. STRATEGY
  • 11.6.5. DEVELOPMENTS
• 11.7. GE HEALTHCARE
  • 11.7.1. OVERVIEW
  • 11.7.2. PRODUCTS & SERVICES
  • 11.7.3. FINANCIALS
  • 11.7.4. STRATEGY
  • 11.7.5. DEVELOPMENTS
• 11.8. IBA GROUP
  • 11.8.1. OVERVIEW
  • 11.8.2. PRODUCTS & SERVICES
  • 11.8.3. FINANCIALS
  • 11.8.4. STRATEGY
  • 11.8.5. DEVELOPMENTS
• 11.9. INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE (POLATOM)
  • 11.9.1. OVERVIEW
  • 11.9.2. PRODUCTS & SERVICES
  • 11.9.3. STRATEGY
  • 11.9.4. DEVELOPMENTS
• 11.10. INSTITUTE OF ISOTOPES CO., LTD.
  • 11.10.1. OVERVIEW
  • 11.10.2. PRODUCTS & SERVICES
  • 11.10.3. STRATEGY
• 11.11. INSTITUTE OF RADIOELEMENT (IRE)
  • 11.11.1. OVERVIEW
  • 11.11.2. PRODUCTS & SERVICES
  • 11.11.3. STRATEGY
  • 11.11.4. DEVELOPMENTS
• 11.12. LANTHEUS MEDICAL IMAGING INC.
  • 11.12.1. OVERVIEW
  • 11.12.2. PRODUCTS & SERVICES
  • 11.12.3. FINANCIALS
  • 11.12.4. STRATEGY
  • 11.12.5. DEVELOPMENTS
• 11.13. NORDION INC.
  • 11.13.1. OVERVIEW
  • 11.13.2. PRODUCTS & SERVICES
  • 11.13.3. FINANCIALS
  • 11.13.4. STRATEGY
  • 11.13.5. DEVELOPMENTS
• 11.14. NTP RADIOISOTOPES (PTY) LTD.
  • 11.14.1. OVERVIEW
  • 11.14.2. PRODUCTS & SERVICES
  • 11.14.3. FINANCIALS
  • 11.14.4. STRATEGY
  • 11.14.5. DEVELOPMENTS
• 11.15. SAMYOUNG UNITECH CO., LTD.
  • 11.15.1. OVERVIEW
  • 11.15.2. PRODUCTS & SERVICES
  • 11.15.3. FINANCIALS
  • 11.15.4. STRATEGY
• 11.16. SIEMENS HEALTHCARE
  • 11.16.1. OVERVIEW
  • 11.16.2. PRODUCTS & SERVICES
  • 11.16.3. FINANCIALS
  • 11.16.4. STRATEGY
  • 11.16.5. DEVELOPMENTS

APPENDIX

• U.S. PATENTS
• EUROPE PATENTS
• JAPAN PATENTS
• WIPO PATENTS

• TABLE 1. GLOBAL RADIOPHARMACEUTICAL MARKET REVENUE, BY APPLICATIONS, 2008 - 2015 ($MILLION)
• TABLE 2. RADIOPHARMACEUTICAL MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 3. RADIOPHARMACEUTICALS IN CLINICAL TRIALS
• TABLE 4. RADIOPHARMACEUTICALS SEGMENTATION
• TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 - 2015 ($THOUSAND)
• TABLE 6. RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 7. NORTH AMERICA: RADIOPHARMACEUTICAL MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 8. FDG MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 9. NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 10. INDICATIONS DIAGNOSED BY TECHNETIUM
• TABLE 11. TECHNETIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 12. NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 13. THALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 14. NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 15. GALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 16. NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 17. SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 18. NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 19. IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 20. NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 21. RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 22. NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 23. SAMARIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 24. NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 25. YTTRIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 26. NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 27. ERBIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 28. NORTH AMERICA: ERBIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 29. OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 30. NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 31. GLOBAL RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY TYPES, 2008 - 2015 ($MILLION)
• TABLE 32. RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 33. NORTH AMERICA: RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 34. INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 35. NORTH AMERICA: INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 36. INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 37. NORTH AMERICA: INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 38. PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 39. NORTH AMERICA: PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 40. OTHER TYPES OF ROUTES OF ADMINISTRATION
• TABLE 41. OTHER ROUTES OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 42. NORTH AMERICA: OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 43. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 - 2015 ($MILLION)
• TABLE 44. DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 45. NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 46. GLOBAL SPECT RADIOPHARMACEUTICALS MARKET, BY TYPES, 2008 - 2015 ($THOUSAND)
• TABLE 47. SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 48. NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 49. TECHNETIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 50. NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 51. GALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 52. NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 53. SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 54. NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 55. IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 56. NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 57. RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 58. NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 59. THALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 60. NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 61. YTTRIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 62. NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 63. OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 64. NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 65. GLOBAL PET RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 - 2015 ($MILLION)
• TABLE 66. PET RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
• TABLE 67. NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRIES, 2008 - 2015 ($MILLION)
• TABLE 68. FDG MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 69. NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 70. OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 71. NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 72. TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 - 2015 ($THOUSAND)
• TABLE 73. TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 74. NORTH AMERICA: TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 75. IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 76. NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 77. RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 78. NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 79. SAMARIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 80. NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 81. ERBIUM MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 82. NORTH AMERICA ERBIUM MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 83. OTHER RADIOPHARMACEUTICALS, BY TYPES
• TABLE 84. OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($THOUSAND)
• TABLE 85. NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 - 2015 ($THOUSAND)
• TABLE 86. NORTH AMERICA: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 87. U.S: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 88. CANADA: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 89. EUROPE: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 90. APAC: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 91. JAPAN: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 92. ROW: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 - 2015 ($THOUSAND)
• TABLE 93. MERGERS & ACQUISITIONS
• TABLE 94. AGREEMENTS & COLLABORATIONS
• TABLE 95. NEW PRODUCT DEVELOPMENT
• TABLE 96. NEW EXPANSION FACILITIES
• TABLE 97. APPROVALS
• TABLE 98. ANSTO HEALTH: MARKET REVENUE, 2008 - 2010 ($MILLION)
• TABLE 99. CARDINAL: MARKET REVENUE, 2008 - 2010 ($MILLION)
• TABLE 100. CARDINAL: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
• TABLE 101. COVIDIEN: MARKET SALES AND R&D EXPENSES, 2008 - 2010 ($MILLION)
• TABLE 102. COVIDIEN: MARKET SALES, BY SEGMENTS, 2008 - 2010 ($MILLION)
• TABLE 103. COVIDIEN: MARKET REVENUE, BY SEGMENT, 2008 - 2010 ($MILLION)
• TABLE 104. COVIDIEN: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
• TABLE 105. FUJIFILM: MARKET REVENUE, 2009 - 2011 ($MILLION)
• TABLE 106. FUJIFILM: MARKET REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
• TABLE 107. FUJIFILM: MEDICAL SYSTEM SEGMENT REVENUE, 2009 - 2011 ($MILLION)
• TABLE 108. FUJIFILM: MARKET REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
• TABLE 109. GE HEALTHCARE: MARKET REVENUE AND R&D EXPENSES, 2007 - 2009 ($BILLION)
• TABLE 110. GE HEALTHCARE: MARKET REVENUE, BY SEGMENT, 2007 - 2009 ($BILLION)
• TABLE 111. GE HEALTHCARE: MARKET REVENUE, BY GEOGRAPHY, 2007 - 2009 ($BILLION)
• TABLE 112. IBA GROUP: TOTAL MARKET REVENUE, 2008 - 2010 ($MILLION)
• TABLE 113. IBA GROUP: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
• TABLE 114. IBA GROUP: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
• TABLE 115. LANTHEUS: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010 ($THOUSAND)
• TABLE 116. LANTHEUS: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($THOUSAND)
• TABLE 117. LANTHEUS: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010 ($THOUSAND)
• TABLE 118. NORDION: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
• TABLE 119. NORDION: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
• TABLE 120. NORDION: MARKET REVENUE, BY COUNTRIES, 2008 - 2010 ($MILLION)
• TABLE 121. SIEMENS HEALTHCARE: TOTAL MARKET REVENUE, 2008 - 2010 ($MILLION)
• TABLE 122. SIEMENS HEALTHCARE: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)

• FIGURE 1. RADIOPHARMACEUTICAL MARKET, BY RADIOISOTOPES, 2008 - 2015
• FIGURE 2. EVOLUTION IN RADIOPHARMACEUTICALS
• FIGURE 3. RADIOPHARMACEUTICALS: MARKET SEGMENTATION
• FIGURE 4. FACTORS DRIVING THE RADIOPHARMACEUTICALS MARKET
• FIGURE 5. RADIOPHARMACEUTICAL MARKET SHARE ANALYSIS, 2010
• FIGURE 6. ANALYSIS OF RADIOPHARMACEUTICALS MARKET, BY END-USERS, 2010
• FIGURE 7. COMPETITIVE LANDSCAPE FOR RADIOPHARMACEUTICALS MARKET
• FIGURE 8. PATENT ANALYSIS, BY ASSIGNEE, 2005 - 2010
• FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY PRODUCTION
• FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET: COMPETITIVE LANDSCAPE

相關商品

核子醫學相關市場調查報告書

法國的核子醫學掃描術診斷設備市場趨勢趨勢:分析及預測
France Nuclear Imaging Market Trends Until 2018
價格 : US $ 2000
出版日期 : 2012年04月

義大利的核子醫學掃描術診斷設備市場趨勢:分析及預測
Italy Nuclear Imaging Market Trends Until 2018
價格 : US $ 2000
出版日期 : 2012年04月

西班牙的核子醫學掃描術診斷設備市場趨勢:分析及預測
Spain Nuclear Imaging Market Trends Until 2018
價格 : US $ 2000
出版日期 : 2012年04月

Markets and Markets發行的醫療設備相關市場調查報告書

口腔清潔用品&牙科用消耗品市場(牙科生技材料·特殊用途產品·修復劑):目前趨勢·市場機會·全球市場預測(∼2016年)

Oral Care Products & Other Dental Consumables Market (Dental Biomaterials, Specialty Products, & Restoratives) Current Trends, Opportunities & Global Forecasts to 2016

價格 : US $ 4650

出版日期 : 2012年04月

牙科用移植&補綴物市場(人工牙齒·假牙·牙冠&牙橋):目前趨勢·市場機會·全球市場預測(∼2016年)

Dental Implants & Prosthetics Market (Artificial Teeth, Dentures, Crowns & Bridges) Current Trends, Opportunities & Global Forecasts to 2016

價格 : US $ 4650

出版日期 : 2012年04月

居家醫療市場(設備·服務·遠端保健/遠端照護):目前趨勢·市場機會·全球市場預測(∼2016年)

Home Healthcare Market (Equipment, Service & Telehealth/Telemedicine) Current Trends, Opportunities & Global Forecasts to 2016

價格 : US $ 4650

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!